Leading global law firm Baker McKenzie announced today that the New York office represented Genomma Lab Internacional ("Genomma") in connection with the divestment of its stake in Mexican pharmaceutical company Marzam.  Headquartered in Mexico City, Genomma specializes in over-the-counter pharmaceutical and personal care products.  Marzam is a leading supplier of pharmaceutical products in Mexico.

Genomma will complete the divestment though its subsidiary Gibart.  Gibart will exit from Marzam by reducing its equity stake in Marzam through a capital increase carried out by one of its existing shareholders, Luis Doporto Alejandre. 

Transactional Practice Group partners Mike Fitzgerald and Arturo Carrillo led the Baker McKenzie team, which also included partners Joy Gallup and Steven Sandretto.

Other law firms participating on this transaction included Creel, García-Cuéllar, Aiza y Enriquez (Mexican counsel to Genomma).

The transaction is part of Genomma's divestment strategy to sell several of its non-core assets to focus on its main brands.

Explore Our Newsroom